Department of Nephrology, Beaumont Hospital, Dublin 9, Ireland.
Ir J Med Sci. 2011 Jun;180(2):429-33. doi: 10.1007/s11845-010-0626-8. Epub 2010 Oct 29.
Steroid therapy is associated with significant morbidity in renal transplant recipients. However, there is concern that steroid withdrawal will adversely affect outcome.
We report on 241 renal transplant recipients on different doses of corticosteroids at 3 months (zero, ≤ 5 mg/day, > 5 mg/day). Parameters analysed included blood pressure, lipid profile, weight change, new onset diabetes after transplantation (NODAT), allograft survival and acute rejection.
Elimination of corticosteroids had no impact on allograft survival at 1 year. There were no cases of NODAT in the steroid withdrawal group compared with over 7% in each of the steroid groups. There were no significant improvements in weight gain, blood pressure control or total cholesterol with withdrawal of steroids before 3 months.
In renal transplant patients treated with tacrolimus and mycophenolate, early withdrawal of steroids does not appear to adversely affect allograft outcome at 1 year. It may result in less NODAT.
类固醇治疗与肾移植受者的显著发病率相关。然而,人们担心类固醇停药会对结果产生不利影响。
我们报告了 241 名肾移植受者在 3 个月时接受不同剂量的皮质类固醇治疗(零、≤ 5mg/天、> 5mg/天)。分析的参数包括血压、血脂谱、体重变化、移植后新发糖尿病(NODAT)、移植物存活率和急性排斥反应。
皮质类固醇的消除对 1 年内移植物存活率没有影响。在类固醇停药组中没有 NODAT 病例,而在每个类固醇组中都有超过 7%的病例。在 3 个月前停用类固醇并没有显著改善体重增加、血压控制或总胆固醇。
在接受他克莫司和霉酚酸酯治疗的肾移植患者中,早期停用类固醇似乎不会在 1 年内对移植物结果产生不利影响。它可能会导致更少的 NODAT。